Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile

Glaukos Corp has raised its 2026 net sales guidance to a range of $620 million to $635 million, up from an earlier midpoint of about $627.5 million, after reporting first?quarter 2026 sales of $150.57 million, according to an analysis of the company’s updated outlook published on May 5, 2026.Sahm Capital as of 05/05/2026 The move highlights sustained demand for its interventional glaucoma implants and keratoconus cross?linking therapies, even as the stock trades below some widely followed fair?value estimates.

As of early May 2026, Glaukos shares traded around $135.85, compared with a commonly cited fair?value estimate of about $151.08, suggesting the market may be discounting execution risk or the company’s still?negative net income despite rapid revenue growth.Sahm Capital as of 05/05/2026 Over the past several years, net sales have climbed from $283 million in 2022 to $315 million in 2023, $383 million in 2024 and $507 million in 2025, reflecting broader adoption of its glaucoma and keratoconus platforms.Stock Titan as of 05/05/2026

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

Glaukos Corp: core business model

Glaukos Corp operates as a hybrid ophthalmic pharmaceutical and medical technology company focused on chronic eye diseases, particularly interventional glaucoma and keratoconus.Stock Titan as of 05/05/2026 The company markets 12 commercial products and advances 13 pipeline programs targeting glaucoma, corneal disease, blepharitis, myopia and retinal conditions, positioning itself at the intersection of devices and drug delivery.Stock Titan as of 05/05/2026

Glaukos emphasizes minimally invasive surgical options and sustained?release therapies that aim to reduce intraocular pressure and slow disease progression, which can lower the need for multiple daily eye drops and more invasive procedures.Stock Titan as of 05/05/2026 Its global infrastructure spans 17 countries with more than 300 commercial personnel, supporting expansion beyond the U.S. into key international markets.Stock Titan as of 05/05/2026

Main revenue and product drivers for Glaukos Corp

Interventional glaucoma implants remain a core revenue driver, with Glaukos’ micro?invasive devices increasingly adopted as part of cataract surgery and standalone procedures to lower intraocular pressure.Stock Titan as of 05/05/2026 Sustained?release therapies that deliver medication over time also contribute to growth, as they align with trends toward fewer daily treatments and better adherence.Stock Titan as of 05/05/2026

In keratoconus, Glaukos markets FDA?approved Photrexa (epi?off) and Epioxa (epi?on) cross?linking therapies, which aim to stabilize the cornea and prevent further vision loss.Stock Titan as of 05/05/2026 The company is advancing a third?generation customized iLink program and additional Phase 2 assets to improve diagnosis, access and long?term treatment of this sight?threatening disease.Stock Titan as of 05/05/2026 Beyond glaucoma and keratoconus, Glaukos is expanding into anterior segment Part D pharmaceuticals and retina, including eyelid?delivered creams for demodex blepharitis and progressive myopia, as well as biodegradable intravitreal implants for conditions such as age?related macular degeneration and diabetic macular edema.Stock Titan as of 05/05/2026

Conclusion

Glaukos Corp’s raised 2026 sales guidance and strong first?quarter revenue underscore its position as a high?growth ophthalmic medtech player with expanding commercial infrastructure and a diversified pipeline.Sahm Capital as of 05/05/2026 The company’s focus on interventional glaucoma, keratoconus and emerging anterior segment and retina programs offers multiple avenues for future revenue, but investors must weigh this against ongoing profitability challenges and valuation sensitivity.Stock Titan as of 05/05/2026 For U.S. investors, Glaukos represents an exposure to a specialized healthcare niche with global growth potential, yet one that carries typical biotech?style execution and regulatory risks.Stock Titan as of 05/05/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.